Cite
HARVARD Citation
Harvey, C. et al. (2015). Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Journal for immunotherapy of cancer. 3 (2), p. 1. [Online].